B Cell Aberrance in Lupus: the Ringleader and the Solution

• Published in: Clinical reviews in allergy & immunology Vol. 62; no. 2; pp. 301 - 323
• Main Authors: Nie, YuXue, Zhao, Lidan, Zhang, Xuan
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.04.2022; Springer; Springer Nature B.V
• Subjects: Allergology; Antibodies, Monoclonal - therapeutic use; Autoantibodies; Autoimmune diseases; Autoimmunity; B cells; B-Lymphocytes; Belimumab; BLyS protein; CD20 antigen; Cell activation; Cell survival; Clinical trials; Costimulator; Cytokines; Dendritic cells; Drug approval; FDA approval; Humans; Immunological tolerance; Immunology; Immunopathogenesis; Immunotherapy; Internal Medicine; Intracellular; Intracellular signalling; Lupus; Lupus Erythematosus, Systemic; Lymphocytes B; Lymphocytes T; Medicine; Medicine & Public Health; Monoclonal antibodies; Systemic lupus erythematosus; T cells; T-Lymphocytes; Therapeutic targets; B cell; Systemic lupus erythematosus; Pathogenesis; Target therapy

Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease with high heterogeneity but the common characterization of numerous autoantibodies and systemic inflammation which lead to the damage of multiple organs. Aberrance of B cells plays a pivotal role in the immunopathogenesis of SLE...